Vaxfab Enterprises board to consider fund raise via QIP, rights issue
- Board meeting scheduled for October 1, 2026
- Agenda includes preferential allotment, rights issue, and QIP
- Trading window closed from September 25, 2026
- Fund raising may involve ADRs, GDRs, or FCCBs

*this image is generated using AI for illustrative purposes only.
Vaxfab Enterprises Limited has scheduled a board meeting for Thursday, October 1, 2026, to deliberate on raising funds through various equity and convertible instruments.
The agenda includes augmenting financial resources via preferential allotment, rights issue, qualified institutional placement (QIP), American Depository Receipts (ADR), Global Depository Receipts (GDR), or Fully Convertible Debentures (FCCB). The company stated these options may be executed in one or more tranches.
Trading window closure
In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for designated persons and their immediate relatives closed on September 25, 2026. It will remain closed until 48 hours after the conclusion of the board meeting.
Board meeting details
The meeting will be held at the registered office of the company in Ahmedabad, Gujarat. The primary business item is to consider and approve the issuance of equity shares or other securities to strengthen the balance sheet.
| Item | Details |
|---|---|
| Meeting Date | October 1, 2026 |
| Venue | Registered Office, Ahmedabad |
| Primary Agenda | Fund raising via equity/convertible instruments |
| Trading Window Closed | September 25, 2026 |
Any other business matters may be transacted with the permission of the Chair. The intimation was filed with BSE Limited and The Calcutta Stock Exchange Limited under Regulation 29 of SEBI (LODR) Regulations, 2015.
Historical Stock Returns for Vaxfab Enterprises
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.21% | +0.82% | -7.91% | +54.76% | +92.14% | +508.61% |
How might the chosen capital raising instrument impact existing shareholders' dilution and earnings per share?
What specific growth initiatives or debt repayment plans will the raised funds be allocated to?
How will the company's choice between domestic instruments (QIP/Rights) and global ones (ADR/GDR) affect its international investor base?


































